JN.1 sub-variant: The Additional Public Health Risk Is Low at the Global Level

JN.1 sub-variant whose earliest documented sample was reported on 25 August 2023 and which was later reported by the researchers to have higher transmissibility and immune escape ability, has now been designated a variant of interest (VOIs) by WHO.

In the last few weeks, JN.1 cases have been reported in many countries. Its prevalence is rapidly increasing globally. In view of rapidly increasing spread, WHO has classified JN.1 as a separate variant of interest (VOI).

As per initial risk evaluation by WHO, the additional public health risk posed by JN.1 sub-variant is low at the global level.

Notwithstanding higher infection rate and possibility of immunity evasion, current evidence does not suggest that the disease severity could be higher compared to other circulating variants.

***

References:

  1. WHO.  Tracking SARS-CoV-2 variants – Currently circulating variants of interest (VOIs) (as of 18 December 2023). Available at https://www.who.int/activities/tracking-SARS-CoV-2-variants
  2. WHO. JN.1 Initial Risk Evaluation 18 December 2023. Available at https://www.who.int/docs/default-source/coronaviruse/18122023_jn.1_ire_clean.pdf?sfvrsn=6103754a_3 

***

Latest

Daraxonrasib Approved for Pancreatic Cancer

Daraxonrasib (Rasonque by Revolution Medicines, Inc.), an inhibitor of...

Glacial Collapse Led to Seismic Event in Nepal 

The magnitude 5.2 seismic event recorded near the border...

Significance of Nancy Grace Roman Space Telescope

Nancy Grace Roman Space Telescope (commonly referred to as...

NASA Invites ISRO to Join Moon Base Programme

NASA has invited ISRO (Indian Space Research Organisation) to...

2026 Total Solar Eclipse

On 12 August 2026, a total solar eclipse was...

AI Designs Complete Functional Genomes

The genome language model Evo 2 has designed novel...

Newsletter

Don't miss

Ukraine crisis: Threat of Nuclear Radiation  

Fire was reported in Zaporizhzhia Nuclear Power Plant (ZNPP)...

Nano-Engineered System for Delivery of Protein Therapeutics to Treat Osteoarthritis

Researchers have created 2-dimensional mineral nanoparticles to deliver treatment...

Green Tea Vs Coffee: The Former Seems Healthier

According to a study conducted among elderly in Japan,...

Alzheimer’s Disease: Coconut Oil Decreases Plaques in Brain Cells

Experiments on mice cells shows a new mechanism pointing...

Climate Change: Greenhouse Gas Emissions and Air Quality are not Two Separate Problems

Climate change as a result of global warming attributed to...

PRIME Study (Neuralink Clinical Trial): Second Participant receives Implant 

On 2nd August 2024, Elon Musk announced that his...
SCIEU Team
SCIEU Teamhttps://www.scientificeuropean.co.uk
Scientific European® | SCIEU.com | Significant advances in science. Impact on humankind. Inspiring minds.

Daraxonrasib Approved for Pancreatic Cancer

Daraxonrasib (Rasonque by Revolution Medicines, Inc.), an inhibitor of the RAS GTPase family has been approved for the treatment of adults with metastatic pancreatic...

Glacial Collapse Led to Seismic Event in Nepal 

The magnitude 5.2 seismic event recorded near the border between Nepal and China on 26 August 2026 at 8:37 AM local time (02:52:10 UTC) has...

Significance of Nancy Grace Roman Space Telescope

Nancy Grace Roman Space Telescope (commonly referred to as Roman Telescope) is set to be launched into space on 30 August 2026. It will...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

For security, use of Google's reCAPTCHA service is required which is subject to the Google Privacy Policy and Terms of Use.

I agree to these terms.